Articles related to CLINICAL STUDY

In this meta analysis of 40 eligible trials involving 35,548 participants and seven diet programs, only the Mediterranean and low-fat diet showed effectiveness in in lowering all cause and CV mortality. Notably, their preventive value increased with increasing CV risk. Diets (with number of studies) included in the meta-analysis:

In a study of patients with DM2, 75 years old and over, continuous glucose monitoring revealed that 65% had glucose level two times below range (<54 mg/dL during ≥15 consecutive minutes) between midnight and 6 a.m. Fewer than half of the patients detected the hypoglycemic episode via self-monitoring. Because hypoglycemia episodes are associated with long-term complications, continuous glucose monitoring (CGM) could be used to improve care in these patients.

Comparing outcomes for all available monoclonal antibody treatments for COVID, this study found the risk for hospitalization or death at 28 days was 4.6% in treated patients and 7.6% in nontreated control patients. Relative risk was somewhat lower for Alpha and Delta variants, and highest for Omicron variants.

The study authors highlight that buprenorphine can be safely started in an emergency department without triggering withdrawal, even among individuals who use stronger opioids like fentanyl. They note, “this study provides further evidence that all emergency department physicians can and should be using buprenorphine to help individuals take the first steps into treatment and toward recovery.”

Frequent use of prescription meds for sleep carries an increased risk for dementia in White older adults compared with those who rarely or never used them, as described in the January issue of Journal of Alzheimer’s Disease. The study found no increased risk for dementia for those who took sleep medications “sometimes.”

The authors evaluated the treatment approaches and outcomes of 110 patients with primary plasma cell leukemia (pPCL) in this retrospective study . Higher complete response rates were associated with treatment with bortezomib, lenalidomide, and dexamethasone (VRd) or daratumumab-based quadruplets (DBQ) and autologous stem-cell transplantation. Patients who received VRd/DBQ had better outcomes than those who received other bortezomib-based combinations or standard chemotherapy.